Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies

Guillerey, Camille, Nakamura, Kyohei, Vuckovic, Slavica, Hill, Geoffrey R. and Smyth, Mark J. (2016) Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cellular and Molecular Life Sciences, 73 8: 1569-1589. doi:10.1007/s00018-016-2135-z


Author Guillerey, Camille
Nakamura, Kyohei
Vuckovic, Slavica
Hill, Geoffrey R.
Smyth, Mark J.
Title Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Journal name Cellular and Molecular Life Sciences   Check publisher's open access policy
ISSN 1420-9071
1420-682X
Publication date 2016-04
Year available 2016
Sub-type Article (original research)
DOI 10.1007/s00018-016-2135-z
Open Access Status Not Open Access
Volume 73
Issue 8
Start page 1569
End page 1589
Total pages 21
Place of publication Basel, Switzerland
Publisher Springer Basel AG
Collection year 2017
Language eng
Abstract Multiple myeloma (MM) is a tumor of terminally differentiated B cells that arises in the bone marrow. Immune interactions appear as key determinants of MM progression. While myeloid cells foster myeloma-promoting inflammation, Natural Killer cells and T lymphocytes mediate protective anti-myeloma responses. The profound immune deregulation occurring in MM patients may be involved in the transition from a premalignant to a malignant stage of the disease. In the last decades, the advent of stem cell transplantation and new therapeutic agents including proteasome inhibitors and immunoregulatory drugs has dramatically improved patient outcomes, suggesting potentially key roles for innate and adaptive immunity in disease control. Nevertheless, MM remains largely incurable for the vast majority of patients. A better understanding of the complex interplay between myeloma cells and their immune environment should pave the way for designing better immunotherapies with the potential of very long term disease control. Here, we review the immunological microenvironment in myeloma. We discuss the role of naturally arising anti-myeloma immune responses and their potential corruption in MM patients. Finally, we detail the numerous promising immune-targeting strategies approved or in clinical trials for the treatment of MM.
Keyword Immune escape
Immune responses
Immunotherapy
Multiple myeloma
Tumor microenvironment
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 02 Feb 2016, 00:31:11 EST by System User on behalf of Learning and Research Services (UQ Library)